Alliance for Multispecialty Research, LLC | AMR Knoxville, TN
Status and phase
Conditions
Treatments
About
This study is to characterize the safety and tolerability of an investigational drug called DONQ52 and consists of a single ascending dose part (Part A) and a multiple ascending dose part (Part B) in well-controlled celiac disease patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
56 participants in 7 patient groups
Loading...
Central trial contact
Clinical trials information
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal